# Geoffrey I. Shapiro
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/geoffrey-i-shapiro/
## Facts
| Field | Value |
| --- | --- |
| Citations | 58,369 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 116 |
| i10-index | 395 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5045419282 |
| ORCID iD | https://orcid.org/0000-0002-3331-4095 |
| Works | 2,057 |
## Researcher papers
Showing 12 of 17.
- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors](https://scholariq.org/papers/activation-of-the-pd-1-pathway-contributes-to-immune-escape-in-egfr-driven-lung/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation](https://scholariq.org/papers/cdk4-6-inhibition-augments-antitumor-immunity-by-enhancing-t-cell-activation/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer](https://scholariq.org/papers/microenvironment-drives-cell-state-plasticity-and-drug-response-in-pancreatic/)
- [Institutional implementation of clinical tumor profiling on an unselected cancer population](https://scholariq.org/papers/institutional-implementation-of-clinical-tumor-profiling-on-an-unselected-cancer/)
- [Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study](https://scholariq.org/papers/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in/)
- [The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers](https://scholariq.org/papers/the-neuroblastoma-associated-f1174l-alk-mutation-causes-resistance-to-an-alk/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
## Researcher university
- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.